Physician profile
John Ekong
NPI 1831536036
$499.47
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $55.97 · 2021: $72.12 · 2022: $70.71 · 2023: $122 · 2024: $65.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $107.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $65.52 | 2024 | Zerbaxa, Recarbrio, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.46 | 2023 | Xifaxan |
| Boston Scientific Corporation | $55.23 | 2022 | |
| Pfizer INC. | $50.95 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $44.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.26 | 2021-2023 | Spevigo |
| Allergan, INC. | $30.85 | 2019 | |
| Novo Nordisk INC | $13.23 | 2019 | |
| Abbott Laboratories | $12.75 | 2019 | |
| Abbvie INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ekong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.